Breaks Categories: News

MondayJan 24, 2022 12:37 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress and the King's College London to utilize psilocybin as part of a psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (“PTSD”) in veterans. According to the update, Combat Stress, the leading charity aiding veterans’ mental health in the United Kingdom, will be one of several sites for Mydecine’s upcoming clinical trials. “The team is thrilled to be conducting studies within the veteran population where the help is needed most,” said…

Continue Reading

ThursdayJan 20, 2022 12:12 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate in the Virtual Investor 2022 Top Picks Conference at 11:00 a.m. ET on Wednesday, Jan. 26, 2022. As part of the virtual event, the company will provide a corporate presentation followed by an interactive Q&A session. In addition to the moderated portion, investors and attendees will have the opportunity to submit questions live during the event or in advance of the conference via www.VirtualInvestorCo.com.…

Continue Reading

ThursdayJan 20, 2022 9:57 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Unveils Newly Designed Corporate Website

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the launch of its newly designed website. According to the update, the new site conveys the company’s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. “We have strategically assembled a team of scientists to help develop our powerful pipeline of next-generation therapeutics,” said Anthony Durkacz, interim CEO of FSD Pharma. “With some of the greatest minds in…

Continue Reading

WednesdayJan 19, 2022 12:09 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Rare Cannabinoid Product Portfolio to Launch CBT

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it has launched B2B sales of the rare cannabinoid cannabicitran (“CBT”) into the health and wellness sector. According to the update, CBT is the first of several new product launches the company has planned for the first half of 2022. “We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand. By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a…

Continue Reading

TuesdayJan 18, 2022 2:12 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), The Newly Partner to Set the Gold Standard for Psychedelic-Assisted Therapies

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with The Newly Institute Inc. (“The Newly”), a Calgary, Alberta based company opening private inter-disciplinary mental health clinics across Canada. The companies will collaborate on expanding psychedelic-assisted psychotherapy to patients and, together, create the package of resources needed for patients and practitioners to successfully gain acceptance into Health Canada's Special Access Program (“SAP”). The Newly is the first partner under Mydecine's recently announced Special Access Support…

Continue Reading

ThursdayJan 13, 2022 1:17 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Launches Miboko – a New Metabolic Health Program

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of Miboko for employers and insurers. Miboko is a new metabolic health program using a non-invasive glucose sensor along with an AI mobile application. The company, aligned with the general trend in consumer digital health care, aims to achieve broad adoption of Miboko as a form of preventative medicine for a wide user base. “Introducing Miboko to the population at-large through employers and insurers will allow Nemaura to reach a much wider audience…

Continue Reading

ThursdayJan 13, 2022 11:29 am

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has unveiled its Special Access Support and Supply Program (“SASSP”). The program provides products, services and support to hospitals, clinics and physicians in Canada who utilize psychedelic-assisted psychotherapy treatment. Health Canada recently added psilocybin and MDMA to its approved list of substances in its Special Access Program (“SAP”), creating an opportunity for MYCOF to provide critical resources in helping thousands of healthcare professionals and clinics offer these treatments to those in need. The Health Canada announcement allows…

Continue Reading

TuesdayJan 11, 2022 1:28 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Latest Episode of Bell2Bell Podcast

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in the Bell2Bell Podcast, a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Mydecine’s co-founder, chairman and CEO Josh Bartch joined the latest episode to discuss the company’s business model, highlighting its phased approach to developing improved treatment options for a variety of underserved indications. “Mydecine Innovations Group… is really focused on first- and second-generation novel therapeutics derived from different psychedelic molecules. We’re using those as a…

Continue Reading

TuesdayJan 11, 2022 9:58 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Closes on $11.5M Private Placement

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has closed on its previously announced private placement. The company announced that the placement was comprised of 12,105,264 shares of common stock (or prefunded warrants) and warrants at a purchase at $0.95 per share or warrant. The placement was valued at approximately $11.5 million gross proceeds for CNSP, which plans to use the funds for clinical trials and preclinical programs as well as other R&D efforts and general corporate purposes. The placement was not…

Continue Reading

MondayJan 10, 2022 1:06 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names Industry Veteran as COO

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has appointed Dr. Arash (Ash) Ghadar as chief operating officer. Currently a non-executive director at Medilink Midlands, Ghadar served for 10 years as the technical director of London-based Datalink Electronics (Datalink), where he managed the design team as an autonomous entity within Datalink. In that capacity, he oversaw the day-to-day operations, business planning, legal affairs, finance, sales and business development of the design team. He also managed numerous technical projects for the company’s healthcare and industrial customers; those…

Continue Reading